A roundup of manufacturing news from Bayer and Ferring Pharmaceuticals. Highlights below. 

* Bayer Opens $44-M Packaging, Logistics Expansion for Consumer Healthcare Products 
* Ferring Pharmaceuticals Opens Gene-Therapy Mfg Site 

---

Bayer Opens $44-M Packaging, Logistics Expansion for Consumer Healthcare Products 
Bayer has opened a $44-million, 70,000-square foot expansion at its facility for consumer healthcare products in Myerstown, Pennsylvania. The company had announced the expansion in 2022. The new space is designed to move products more efficiently with eight new product packaging lines and automated systems in logistics.  

Source: Bayer 

---

Ferring Pharmaceuticals Opens Gene-Therapy Mfg Site 
Ferring Pharmaceuticals, a Saint-Prex, Switzerland-based bio/pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has approved its 12,000-square-foot drug-product manufacturing facility in Parsippany, New Jersey, to produce the company’s gene therapy, Adstiladrin (nadofaragene firadenovec-vncg), for treating certain forms of bladder cancer.  

The approval expands Ferring’s manufacturing capabilities to three sites dedicated for Adstiladrin and secures a final $200-million payment from Royalty Pharma as part of a royalty-based financing agreement announced in 2023. The company also manufactures the product at existing manufacturing sites in Kuopio, Finland. 

Adstiladrin is an intravesical non-replicating gene therapy approved by the FDA for patients with high-risk Bacillus Calmette-Guérin (unresponsive) non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. 

Source: Ferring Pharmaceuticals